Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. issued 3,213,583 shares of common stock to satisfy the earnout consideration tied to its acquisition of RedWave Technology. These shares fulfill the company’s obligations under the April 29, 2024 Equity Purchase Agreement with CAM3 HoldCo, LLC and related sellers. The earnout was based on revenue from certain RedWave products and services over the period from May 1, 2024 through April 30, 2026, measured against a $37 million revenue threshold set in the agreement. With this issuance, the company states that its earnout obligations under the purchase agreement are now fully satisfied.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 222 shares of common stock at a weighted average price of $9.07 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
After this sale, Knopp directly holds 732,603 shares of common stock. Separately, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed a beneficial owner.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of common stock. On July 2, 2026, he sold 2,200 shares at a weighted average price of $9.02 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he directly holds 843,359 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 20,000 shares of common stock at a weighted average price of $8.84 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
Following this sale, Brown directly holds 845,559 shares of 908 Devices common stock. Because the sale was carried out pursuant to a Rule 10b5-1 plan, the timing reflects a preset trading arrangement rather than a discretionary decision based on recent company developments.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 2,798 shares of common stock at a weighted average price of $9.09 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
Following the sale, Knopp directly holds 732,825 shares of common stock. In addition, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law serves as trustee and has sole voting and dispositive control; Knopp may be deemed the beneficial owner of those securities.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 9,900 shares of common stock at a weighted average price of $9.04 per share. The trades were executed at prices ranging from $9.00 to $9.08.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After the sale, Brown directly holds 865,559 shares of 908 Devices common stock, indicating he retains a substantial equity position in the company.
908 Devices Inc. President and CEO Kevin J. Knopp reported open‑market sales of 60,345 shares of common stock over three days at prices around $9.06–$9.14 per share. These transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on May 20, 2025, indicating they were pre‑scheduled.
After these sales, Knopp directly holds 735,623 shares of 908 Devices common stock. In addition, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother‑in‑law serves as trustee with sole voting and dispositive power, and of which Knopp may be deemed the beneficial owner.
908 Devices Inc. director Michele M. Leonhart exercised restricted stock units into common shares as part of equity compensation. She acquired 6,486 shares of common stock through the conversion of 6,486 restricted stock units at a stated price of $0.00 per share.
Following the transaction, Leonhart directly holds 27,054 shares of common stock. The restricted stock units underlying this exercise vest in substantially equal annual installments over three years starting June 25, 2024, with prorated vesting if service ends earlier, and represent the right to receive one share of common stock per unit when vested.
AWM Investment Company, Inc., a greater-than-10% owner of 908 Devices Inc., reported open-market sales of the company’s common stock through limited partnerships it advises. On June 22 and 23, the funds sold a total of 7,718 shares at prices around $9 per share. After these trades, entities advised by AWM indirectly held 4,879,773 shares of common stock, spread across several Special Situations funds. AWM is described as having sole voting and investment power over these fund holdings, while formally disclaiming beneficial ownership except to the extent of its pecuniary interest.